Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.

EClinicalMedicine · 2023 · PMC10102537 · PMID 37223439

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

showed a trendP = 0.073so close (0.05 < p ≤ 0.1)

AXA1125-treated patients showed a trend towards reduction in post-exertional peak serum lactate level from baseline at Day 28 compared with placebo (LS mean difference, −0.42; 95% CI –0.89, 0.04; P = 0.073 ) .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.